LowellL.HartMD

Oncology • Fort Myers, FL

Physician

Join to view full profile

Dr. Hart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hart's full profile

Already have an account?

Office
Florida Cancer Specialists (COL)
8931 Colonial Center Drive, Suite 300
Fort Myers, FL 33905
Phone+1 239-938-0800

Fax+1 239-938-0890
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1983 - 1986
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1980 - 1983
SUNY Upstate Medical UniversityClass of 1980

Certifications & Licensure

FL State Medical License 1981 - 2026
NC State Medical License 2016 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Gulfshore Life Magazine: Top Doctors Castle Connolly, 2004, 2006-2014
CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014
Top Doctors: Florida Castle Connolly, 2000
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
Completed
Phase 1, Phase 2
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
Completed
Phase 1, Phase 2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07
Terminated
Phase 1, Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Lowell Hart, Augustina Ogbonnaya, Kristen Boykin, Kathryn Deyoung, Ray Bailey, Trevor Heritage, Lorena Lopez-Gonzalez, Huan Huang, Lucio Gordan> ;Cancer Medicine. 2023 Apr 1
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
25 citations
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock-Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. H...> ;British Journal of Cancer. 2021 Aug 31
14 citations
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
12 citations
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
, , , , , , , , , , , , , , , , , > ;NPJ Breast Cancer. 2021 Jun 11
62 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
37 citations
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy S. Clark, Amelia Zelnak, Denise A. Yardley, Meghan Sri Karuturi, Tara Sanft, Sibel Blau, Lowell L. Hart, Cynthia ...> ;Clinical Cancer Research. 2021 Aug 1
7 citations
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage sm...
Chao Li, Lowell L. Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Sao Pedro Rocha Lima, Paul Conkling, Roy Timothy Webb, Robert M. Jotte, Steven R. Schuster, Wil...> ;Cancer Chemotherapy and Pharmacology. 2021 Feb 17
16 citations
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia Cristina Tudor, M.T. Huizing, Rob...> ;Breast Cancer Research and Treatment. 2021 Feb 16
39 citations
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, pl...
Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, Oleksandr Ivashchuk, Sreekanth Reddy, Jana Jaal, Iveta Kudaba, Lowell L. Hart, Amiran Matitashvili, Yili Pritchett,...> ;International Journal of Cancer. 2021 May 15
5 citations
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-...
Jesus G. Berdeja, Tara K. Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, Ian W. Flinn, Jeffrey V. Matous> ;American Journal of Hematology. 2021 Jan 9
63 citations
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart, Renata Ferrarotto, Z. Andric, J. Thaddeus Beck, Janakiraman Subramanian, Davorin Radosavljevic, Bojan Zaric, Wahid Hanna, Raid Aljumaily, Taofeek K. Ow...> ;Advances in Therapy. 2021 Jan 1
24 citations
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Ian E. Krop, Vandana G. Abramson, Marco Colleoni, Tiffany A. Traina, Frankie A. Holmes, Laura García-Estévez, Lowell L. Hart, Ahmad Awada, Claudio Zamagni, Patrick G. ...> ;Clinical Cancer Research. 2020 Sep 28
15 citations
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
Edgardo S. Santos, Lowell L. Hart> ;Oncotargets and Therapy. 2020 Sep 22
26 citations
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris ...> ;British Journal of Clinical Pharmacology. 2020 Sep 1
91 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
39 citations
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, Neal Evan Rothschild, Lynn E. Spitler, C. Lance Co...> ;Cancer. 2019 Apr 1
10 citations
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Ward, Bhuvaneswar...> ;Clinical Breast Cancer. 2019 Feb 28
32 citations
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Petros Grivas, Amir Mortazavi, Joel Picus, Noah M. Hahn, Matthew I. Milowsky, Lowell L. Hart, Ajjai Alva, Joaquim Bellmunt, Sumanta K. Pal, Richard Martin Bambury, Pet...> ;Cancer. 2019 Feb 15
8 citations
Cabazitaxel Plus Lapatinib as Therapy for HER2 + Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study
Denise A. Yardley, Lowell L. Hart, Patrick J. Ward, Gail Lynn Shaw Wright, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth> ;Clinical Breast Cancer. 2018 Oct 1
126 citations
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cance...
Karen A. Autio, Robert Dreicer, Justine Anderson, Jorge A. Garcia, Ajjai Alva, Lowell L. Hart, Matthew I. Milowsky, Edwin M. Posadas, Charles J. Ryan, Ryon P. Graf, Ry...> ;JAMA Oncology. 2018 Oct 1
53 citations
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans L. G. Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Jakobsen, Emilio Alba, Erik Wist, Anne Favret...> ;Breast Cancer Research and Treatment. 2018 Feb 1
147 citations
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Daniel D. Von Hoff, Monica M. Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald Parson...> ;Clinical Cancer Research. 2016 Feb 4
76 citations
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Joyce O'Shaughnessy, Katarína Petráková, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph ...> ;Breast Cancer Research and Treatment. 2018 Feb 1
33 citations
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris, Carla Kurkjian, Lowell L. Hart, Shubham Pant, Patrick Murphy, Suzanne F. Jones, Rachel Neuwirth, Chirag Patel, F. Zohren, J. R. Infante> ;Cancer Chemotherapy and Pharmacology. 2017 Jun 10
Join now to see all

Lectures

Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung CancerAugust 15th, 2019
G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1st, 2019
Sarah Cannon to Present Latest Cancer Research Insights at 2019 American Society of Clinical Oncology’s Annual MeetingMay 30th, 2019